We are a group of Pharmaceutical Industry Executives, Military Vets, and Civic Volunteers dedicated to averting Public Health crisis related to Lead Poising, Radiation Poisoning, and other toxic heavy metals found in and around the environment in both the U.S. and developing nations.Captura is developing a drug called C2E2 for treatment of individuals who have been contaminated by highly radioactive compounds, either by accident or following a nuclear terrorism event. C2E2 is a ‘radionuclide decorporation agent' that works by binding radioactive elements in the bloodstream and enhancing their elimination before they can be trapped inside the liver and bones where they can do maximum damage.Because C2E2 can be taken orally, it has significant advantages over existing radionuclide decorporation agents (e.g. DTPA), which must be administered by repeated intravenous injection in the presence of a trained caregiver, thereby reducing its utility.C2E2 can also be used to treat and remove gadolinium (used in MRI studies) and heavy metals, most notably lead, from the human body.